Dredge, K; Marriott, JB; Macdonald, CD; Man, HW; Chen, R; Muller, GW; Stirling, D; Dalgleish, AG (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. BRITISH JOURNAL OF CANCER, 87 (10). 1166 - 1172 (7). ISSN 0007-0920 https://doi.org/10.1038/sj.bjc.6600607
SGUL Authors: Dalgleish, Angus George

Preview

["document_typename_application/pdf; charset=binary" not defined] Published Version Download (293kB) | Preview

Item Type:	Article
Additional Information:	PubMed ID: 12402158
Keywords:	3',5'-Cyclic-AMP Phosphodiesterases, Angiogenesis Inhibitors, Animals, Cell Division, Cell Movement, Cyclic Nucleotide Phosphodiesterases, Type 4, Endothelium, Vascular, Female, Humans, Immunosuppressive Agents, Male, Mice, Rats, Thalidomide, Tumor Necrosis Factor-alpha, Science & Technology, Life Sciences & Biomedicine, Oncology, thalidomide analogues, anti-angiogenic, immunomodulatory, IMiDs, SelCIDs, ENDOTHELIAL-CELL PROLIFERATION, MULTIPLE-MYELOMA, U937 CELLS, TNF-ALPHA, IN-VITRO, CANCER, SURAMIN, GROWTH, ACTIVATION, INHIBITION, thalidomide analogues, anti-angiogenic, immunomodulatory, IMiDs, SelCIDs
SGUL Research Institute / Research Centre:	Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title:	BRITISH JOURNAL OF CANCER
ISSN:	0007-0920
Related URLs:	Author
Dates:	Date Event 4 November 2002 Published
Web of Science ID:	WOS:000179326600017
	Download EPMC Full text (PDF)
	Download EPMC Full text (HTML)
URI:	https://openaccess.sgul.ac.uk/id/eprint/718
Publisher's version:	https://doi.org/10.1038/sj.bjc.6600607

Actions (login required)

Edit Item